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[Percy Bysshe Shelley]
New genomic technologies and epigenetic research are unraveling
the pathophysiological pathways underlying neurological and psychiat-
ric diseases, including Alzheimer's disease, Parkinson's disease,multiple
sclerosis, autism, migraine, schizophrenia, major depression, and other
disorders of the nervous system. Interactions between genetic factors,
epigenetic proﬁle, environmental risk and other pathological mecha-
nisms are being dissected with increasing depth. The identiﬁcation of
molecular mechanisms, such as aberrant gene silencing, over expres-
sion or production of toxic RNAs and/or proteins, reveals the impor-
tance of genomic regulation. While this brings hope for improved
therapeutics, translational neurogenomics is challenged by the variabil-
ity in disease penetrance and spectrum of clinical manifestations, sever-
ity and evolution. Furthermore, although new molecular discoveries
and bioinformatics programs are rapidly improving diagnostic algo-
rithms and laboratory methods, the application of this new genomic
knowledge to appropriate clinical care has yet to be fully validated.
This special issue of the Journal of Applied & Translational Genomics
(ATG) addresses a variety of subjects in this rapidly advancing arena,
and with a broad geographical representation.
The paper by Dodgen and collaborators, who did not ﬁnd association
between CYP2D6 polymorphisms and risperidone adverse effects in the
South African population, covers the ﬁeld of neuro-pharmacogenomics.
These authors identiﬁed a novel CYP2D6 polymorphism in this popula-
tion, emphasizing the need to investigate populations of different an-
cestries before the clinical use of pharmacogenetic markers can be
translated to non-Caucasians. Neuro-pharmacogenomics is also ad-
dressed by Benitez and coworkers, who investigated the clinical validity
and utility of combinatorial pharmacogenomics to improve psychiatric
medication selection. They stress the importance of clinical education
about the beneﬁts of pharmacogenomic testing in psychiatry in order
to optimize treatment decisions and improve patient outcome. Karikari
and Aleksic highlight the potential impact that neurogenomics research
can have on Africa's science and healthcare. Among the reasons that
make the African continent promising to shed new light on the geno-
mics of neuropsychiatric and developmental diseases are its diversity
of genetic makeup and gene–environment interactions and the op-
portunity of traditional medicine for drug discovery. Some chal-
lenges, on the other hand, include the scarcity of trained clinical
specialists and neuroscientists, sustainable funding and ethical im-
plications of genetic data misuse on vulnerable participants. The
commentary “Neurogenomics: An Egyptian Perspective” brings an
excellent addition to the current issue of ATG, as it highlights thehttp://dx.doi.org/10.1016/j.atg.2015.06.003
2212-0661/© 2015 Elsevier B.V. All rights reserved.situation of neurogenomics in Egypt, one of the biggest African
countries. The authors underscore various challenges and also pro-
pose possible solutions. This is in accordance with the commentary
by Karikari and Quansah who discuss the challenges and opportuni-
ties for neurogenomics in Ghana. Both commentaries emphasize
that improved funding and policy support for neurogenomics re-
search would be important to attract and equip the best-trained sci-
entists in this area. Mohamed and colleagues study the NDUFA12L
mitochondrial complex-I assembly factor, showing a nice example
of neuroscience research carried out in Africa. These authors con-
clude that polymorphisms in NDUFA12L may play a crucial role in
the development of neurodegenerative tauopathies, and suggest
that NDUFA12L screening might be used to identify risk groups for
such disorders. On the other hand, a research paper by Saxena and
colleagues presents the Asian work in neuroscience. These authors
demonstrate a role for antioxidant enzymes in chronic brain ische-
mia using a rat model with bilateral occlusion of the common carot-
id arteries. This link between oxidative stress and progressive
neuronal damage in chronic ischemia may open up therapeutic
strategies.
These and other advances in neurogenomics are the basis for novel
medical applications, thus ﬁnding their way into the clinical arena.
The report of a young patient with progressive spastic paraplegia diag-
nosed with SPG11, by Cristina Castro and colleagues, inaugurates a sec-
tion in the journal dedicated to genomics case reports. The authors
emphasize the importance of combining high-throughput sequencing
technologies with skilled, thorough clinical evaluation in order to max-
imize the diagnostic efﬁcacy of next generation sequencing. When it
comes to diagnosing genetic neuropsychiatric disorders with genomic
analyses, psychological and ethical questions that have to be handled
appropriately arise. This is the focus of the paper by Ryan and co-
workers, who review the context of genetic counseling in adolescent
psychiatry. The authors provide insightful reﬂections on themain issues
and address some elements of the genetic counseling protocol that may
help maximize its beneﬁts and minimize potential harm. In a broader
sense, handling ethical, legal and social issues is a challenge for
any genomic research on neuropsychiatric and neurodevelopmental
disorders, since the traits investigated are related with the very es-
sence of human individuality: cognition, personality and behavior.
This is the focus of the paper by Canli and collaborators, who refer
to neurogenethics as an emerging discipline at the intersection of
ethics, neuroscience and genomics.
Finally, we would like to express our deep gratitude to the authors
and reviewers of this Special Issue. We hope that you will ﬁnd these ar-
ticles instructive and thought provoking. We welcome your opinions
2 Editorialand feedback about this issue of ATG, as well as Letters to the Editor.
Please send your comments to the editorial ofﬁce.
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